B3GALT4

B3GALT4 encodes a Mn2+-dependent UDP-galactose:beta-N-acetylgalactosamine beta-1,3-galactosyltransferase that synthesizes GM1 and GD1b gangliosides by transferring galactose in a beta-1,3 linkage onto GalNAc-containing glycolipid acceptors, as established by direct enzymatic characterization of the recombinant enzyme (PMID:9582303). Because its ganglioside products serve as the cholera toxin receptor, B3GALT4 is functionally required for cholera toxin intoxication, with loss of function abolishing CTx-mediated cytotoxicity (PMID:22123862). The GM1 it produces is cytoprotective: knockdown in dopaminergic cells lowers GM1 and increases vulnerability to MPP+ neurotoxicity, a phenotype reversed by exogenous GM1 (PMID:30611881). Through its control of ganglioside composition and lipid raft formation, B3GALT4 modulates downstream signaling — regulating c-Met within lipid rafts and the AKT/mTOR/IRF-1 axis to control CXCL9/CXCL10 secretion and CD8+ T cell recruitment in neuroblastoma (PMID:36284313), and acting through AKT/mTOR to restrain autophagy and promote proliferation, migration, and invasion in breast cancer cells (PMID:39331217). No structural model or disease-causative mutation is reported in the available corpus.

1. 1996 High

   Before its molecular identity was clear, it was unknown what reaction the GalT-4 activity catalyzed; biochemical purification defined a metal-dependent galactosyltransferase acting on glycolipid acceptors requiring a terminal GlcNAc residue.

   Evidence 107,500-fold enzyme purification from mouse T-lymphoma with kinetic and substrate-specificity characterization

   PMID:8781973

   Open questions at the time

   • Activity characterized as beta-1,4 galactosylation of lactotriaosylceramide, not yet linked to the GM1/GD1b ganglioside pathway
   • Gene identity not established at this stage
2. 1998 High

   It was unknown which cloned gene encoded this transferase and what ganglioside products it made; recombinant expression assigned B3GALT4 as a beta-1,3-galactosyltransferase in GM1/GD1b synthesis.

   Evidence Baculovirus expression and in vitro galactosyltransferase assay on GalNAc acceptors

   PMID:9582303

   Open questions at the time

   • No structural model of the catalytic domain
   • Cellular and physiological roles not addressed
3. 1998 Medium

   To confirm the catalytic domain identity, the question was whether a minimal recombinant fragment retains activity; a truncated GST-fusion form expressed in bacteria reproduced native enzyme activity.

   Evidence Recombinant GST-fusion expression in E. coli with activity and acceptor-interaction studies

   PMID:9821875

   Open questions at the time

   • Limited mechanistic detail beyond abstract
   • Avian ortholog, not human enzyme
4. 2011 High

   Whether B3GALT4 was functionally required for ganglioside-dependent cellular processes was untested; a genetic screen showed it is essential for cholera toxin intoxication via ganglioside receptor biosynthesis.

   Evidence Haploid loss-of-function genetic screen in human cells with cytotoxic CTx conjugate

   PMID:22123862

   Open questions at the time

   • Does not address neuronal or oncogenic roles
   • Screen identifies pathway requirement, not direct receptor binding
5. 2019 Medium

   The physiological consequence of B3GALT4-dependent GM1 in neurons was unknown; knockdown lowered GM1 and sensitized dopaminergic cells to neurotoxin, with GM1 rescue establishing a cytoprotective role.

   Evidence siRNA knockdown in SK-N-SH cells with ganglioside measurement, MPP+ toxicity assay, and GM1 rescue

   PMID:30611881

   Open questions at the time

   • Single cell line, single lab
   • In vivo relevance to Parkinsonian neurodegeneration not tested
6. 2022 Medium

   How B3GALT4-controlled gangliosides influence tumor signaling and immunity was unclear; in neuroblastoma it was shown to regulate GD2 and lipid rafts, modulating c-Met/AKT/mTOR/IRF-1 signaling and CD8+ T cell recruitment.

   Evidence Silencing/overexpression with flow cytometry, ELISA, raft inhibition, and in vivo tumor model

   PMID:36284313

   Open questions at the time

   • Single lab
   • Direct mechanistic link between raft ganglioside changes and c-Met not fully resolved
7. 2024 Medium

   Whether B3GALT4 influences tumor cell behavior beyond immune signaling was open; in breast cancer it was shown to promote proliferation/invasion and restrain autophagy through AKT/mTOR.

   Evidence Overexpression/knockdown with autophagy assays, LC3 imaging, RNA-seq/GSEA, and in vivo assays

   PMID:39331217

   Open questions at the time

   • Single lab
   • Connection between glycosyltransferase activity and AKT/mTOR not mechanistically dissected

• How B3GALT4's enzymatic ganglioside output is mechanistically coupled to AKT/mTOR signaling and lipid raft organization across tissues remains unresolved.
• No structural model of the human enzyme
• No reported disease-causative mutation
• Causal chain from specific ganglioside species to receptor-tyrosine-kinase signaling undefined